Back to Trials
NCT06693687NARecruiting

A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

M.D. Anderson Cancer Center

Start Date

12/18/2024

Completion Date

11/1/2027

Summary

To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.

Detailed Description

Primary Objective • To determine the rate of therapy discontinuation due to toxicity among patients using ApricityCare. Secondary Objectives • To evaluate time the ease and experience of patient use of ApricityCare (i.e., patient engagement) in reporting symptoms during their systemic cancer treatments. Furthermore, the frequency of patient symptom reporting via check-in to ApricityCare will be evaluated, as will the time taken to respond and engage patients after they report toxicity or other adverse events via ApricityCare.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Age 18 years of age or older * Confirmed diagnosis of cancer * Part 1 (Run-in Phase): Only patients with prostate, kidney, and/or bladder cancer will be enrolled with either localized or metastatic disease. * Part 2 (Expansion Phase): Metastatic patients will be enrolled. Note, evaluable metastatic patients from Ppart 1 will be counted in Cohort A as described in section 8.4. * Planned to receive systemic anti-cancer therapy * Ability to understand and the willingness to sign a written informed consent document * Ability to speak, read, and understand one of the following languages: English, Spanish, Mandarin and Cantonese Chinese * Ownership of a smartphone and willingness to use it as outlined by the protocol and described in the ICF Exclusion Criteria: \- Have any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study (pregnancy is not exclusionary and pregnant women will be permitted to enroll in the study).

Interventions

BEHAVIORAL

Metastatic Cancer

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Metastatic Cancer

Locations

MD Anderson Cancer Center

Houston, Texas 77030

United States